Research progress in prostacyclins in treatment of pulmonary hypertension
-
摘要: 肺动脉高压是肺高血压的一类，可危及生命。以肺动脉压力升高、肺血管阻力增加为主要特征，进而导致右心衰竭和死亡。前列环素信号通路是肺动脉高压重要的通路之一，除前列环素类似物和前列环素IP受体激动剂外，作用于血栓素A2的药物也正处于研究中。此外，还有更多新型治疗药物进入临床试验。本文通过对上述药物的简要介绍，以期为治疗肺动脉高压的治疗提供参考。Abstract: Pulmonary arterial hypertension, a type of pulmonary hypertension, is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, leading to right heart failure and death. Prostacyclin signaling pathway is one of the important pathways of pulmonary arterial hypertension. In addition to prostacyclin analogs and prostacyclin IP receptor agonists, drugs acting on thromboxane A2 are also under study. In addition, more new therapeutic drugs are entering clinical trials. This paper briefly introduces the above drugs in order to provide reference for the treatment of pulmonary hypertension.
-
Key words:
- pulmonary arterial hypertension /
- prostacyclin /
- treatment progress
-
[1] 中华医学会心血管病学分会肺血管病学组, 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(12): 933 – 964. doi: 10.3760/cma.j.issn.0253-3758.2018.12.006 [2] Coeytaux RR, Schmit KM, Kraft BD, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Chest, 2014, 145(5): 1055 – 1063. doi: 10.1378/chest.13-1864 [3] Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives[J]. Eur Respir J, 2019, 53(1): 1801887. doi: 10.1183/13993003.01887-2018 [4] Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension[J]. J Lab Clin Med, 2001, 138(5): 287 – 297. doi: 10.1067/mlc.2001.119329 [5] Sitbon O, Vonk Noordegraaf A. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience[J]. Eur Respir Rev, 2017, 26(143): 160055. doi: 10.1183/16000617.0055-2016 [6] Grünig E, Benjamin N, Lange TJ, et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial[J]. Respiration, 2016, 92(6): 362 – 370. doi: 10.1159/000450759 [7] Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial[J]. Chest, 2012, 142(6): 1383 – 1390. doi: 10.1378/chest.11-2212 [8] Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension[J]. Respir Med, 2010, 104(5): 731 – 740. doi: 10.1016/j.rmed.2010.01.008 [9] Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension[J]. Eur Respir J, 2009, 33(6): 1354 – 1360. doi: 10.1183/09031936.00169608 [10] Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial[J]. J Am Coll Cardiol, 2002, 39(9): 1496 – 1502. doi: 10.1016/S0735-1097(02)01786-2 [11] Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2003, 41(12): 2119 – 2125. doi: 10.1016/S0735-1097(03)00463-7 [12] Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J]. Eur Respir J, 2012, 40(4): 874 – 880. doi: 10.1183/09031936.00137511 [13] Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2015, 373(26): 2522 – 2533. doi: 10.1056/NEJMoa1503184 [14] Picken C, Fragkos KC, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis[J]. J Clin Med, 2019, 8(4): 481. doi: 10.3390/jcm8040481 [15] Roscigno R, Vaughn T, Anderson S, et al. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil[J]. Pulm Circ, 2020, 10(4): 2045894020971509. doi: 10.1177/2045894020971509 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 74
- HTML全文浏览量: 4
- PDF下载量: 13
- 被引次数: 0